May 18, 2017 10:05 am UTC| Business
NEW YORK, May 18, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 22nd European Hematology...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...
May 18, 2017 10:03 am UTC| Business
AMES, Iowa, May 18, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...
May 18, 2017 10:03 am UTC| Business
AMES, Iowa, May 18, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic...
May 18, 2017 10:03 am UTC| Business
AMES, Iowa, May 18, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic...